Novick A C, Kaye M C, Cosgrove D M, Angermeier K, Pontes J E, Montie J E, Streem S B, Klein E, Stewart R, Goormastic M
Department of Urology, Cleveland Clinic Foundation, OH 44195.
Ann Surg. 1990 Oct;212(4):472-6; discussion 476-7. doi: 10.1097/00000658-199010000-00010.
From June 1984 to September 1989, 43 patients with large vena caval tumor thrombi from retroperitoneal malignancies underwent surgical treatment with cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA). The primary malignancies were renal cell carcinoma (RCC) (n = 39), renal pelvic transitional cell carcinoma (n = 1), adrenal pheochromocytoma (n = 1), and renal (n = 1) or retroperitoneal (n = 1) sarcoma. The level of the caval thrombus was either suprahepatic (n = 27), intrahepatic (n = 14), or subhepatic (n = 2). In all cases the primary tumor and caval thrombus were completely removed. Concomitant procedures included coronary artery bypass grafting (n = 5), pulmonary resection (n = 2), and hepatic lobectomy (n = 1). The time of circulatory arrest ranged from 10 to 44 minutes (mean, 23.5 minutes). There were two operative deaths (4.7%), neither of them due to to the use of DHCA. Major postoperative complications occurred in 13 patients (30.2%). There were no ischemic or neurologic complications and no cases of perioperative tumor embolization. The median postoperative hospital stay was 9 days. Twenty-two patients (51%) are alive and enjoying a good quality of life. The 3-year patient survival rates in patients with localized (n = 24) versus metastatic (n = 15) RCC are 63.9% and 10.9%, respectively (p = 0.02). We conclude that CPB with DHCA facilities excision of retroperitoneal malignancies with large caval thrombi and provides the potential for cure with low morbidity and mortality rates.
1984年6月至1989年9月,43例患有来自腹膜后恶性肿瘤的大静脉腔肿瘤血栓的患者接受了体外循环(CPB)和深低温循环停搏(DHCA)下的手术治疗。原发性恶性肿瘤为肾细胞癌(RCC)(n = 39)、肾盂移行细胞癌(n = 1)、肾上腺嗜铬细胞瘤(n = 1)以及肾(n = 1)或腹膜后(n = 1)肉瘤。腔静脉血栓的位置为肝上(n = 27)、肝内(n = 14)或肝下(n = 2)。所有病例中,原发性肿瘤和腔静脉血栓均被完全切除。同期手术包括冠状动脉搭桥术(n = 5)、肺切除术(n = 2)和肝叶切除术(n = 1)。循环停搏时间为10至44分钟(平均23.5分钟)。有2例手术死亡(4.7%),均非因使用DHCA所致。13例患者(30.2%)发生了主要术后并发症。未出现缺血或神经并发症,也没有围手术期肿瘤栓塞病例。术后中位住院时间为9天。22例患者(51%)存活且生活质量良好。局限性(n = 24)与转移性(n = 15)RCC患者的3年生存率分别为63.9%和10.9%(p = 0.02)。我们得出结论,CPB联合DHCA有助于切除伴有大腔静脉血栓的腹膜后恶性肿瘤,并有可能实现低发病率和死亡率的治愈。